

**SUBCLONING OF CYTOCHROME P450 2C19 (CYP2C19)
IN *ESCHERICHIA COLI* STRAIN BL21**

by

NUR AZIEYATI BINTI ABDULLAH

**Dissertation submitted in partial fulfilment of requirements for the Degree of
Bachelor of Health Science (Biomedicine)**

March 2011

ACKNOWLEDGEMENT

In name of ALLAH, The Most Gracious and The Most Merciful. Thanks to Him for giving me the strength and patient in completing this project.

Firstly, I would like to convey my gratitude and thank you to my supervisor, Associate Professor Dr. Hamid Fauzi for his invaluable guidance, understanding, patience, supports and his passions to handle me throughout the completion of this thesis. I also would like to express my deepest gratitude and appreciation to Professor Rusli Ismail, Director of Institute for Research in Molecular Medicine (INFORMM) for giving me an opportunity to do my final year project here.

Very special thank and appreciation to Dr. See Too Wei Cun as the course coordinator and other lecturers for their support and guidance. My deepest appreciation goes to my father, Abdullah bin Che Mat and my mother, Maimun binti Mahmud and my siblings for the enormous amount of love, support, encouragement and sacrifice that they had given to me.

This appreciation also goes to all members of RNOmics/Cell culture, Chromatography and other labs for their untiring assistance and guidance. Thank you also to all my friends especially to my project partners and also my beloved classmate for their opinions and concern throughout my study.

Last but not least, my special thanks dedicated to all panelists for their devoted time and tireless effort and to all people who are directly or indirectly contributed to the completion for this study. Thank you.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	i
TABLE OF CONTENTS	ii
LIST OF FIGURES	iv
LIST OF TABLES	v
LIST OF ABBREVIATIONS	vi
LIST OF SYMBOLS	viii
ABSTRAK	ix
ABSTRACT	x
CHAPTER 1 INTRODUCTION	1
1.1 Background of Study	1
1.1.1 Pharmacogenomics	1
1.1.2 Role of Pharmacogenomics in Reducing Adverse Drug Reactions ..	2
1.1.3 The Importance of Cytochrome P450 Study	3
CHAPTER 2 LITERATURE REVIEW	4
2.1 Human Drug Metabolism	4
2.2 Clinical Relevance of Drug Metabolism	6
2.2.1 Genetic Polymorphism	6
2.2.2 Induction or Inhibition and Environmental Factors	7
2.2.3 Age and Sex	9
2.2.4 Disease States	9
2.3 Cytochrome P450	10
2.4 Classification of Cytochrome P450	13
2.5 CYP2C Family	16
2.6 CYP2C19 Subfamily	17
2.6.1 Effects of CYP2C19 Polymorphism on Drug Metabolism and Response	23
2.6.2 Association between CYP2C19 Polymorphism and Disease	23
2.7 Clinical Implications	25
2.8 Gene Cloning	26
2.9 Objectives	29
2.10 Flow Chart of Study	30

CHAPTER 3	MATERIALS AND METHODOLOGY	31
3.1	Chemicals and Reagents	31
3.2	Instruments	31
3.3	Methodology.....	34
	3.3.1 Subcloning of CYP2C19	34
	3.3.2 Preparation of Luria-Bertani (LB) Broth and Agar Plates.....	35
	3.3.3 Preparations of <i>Escherichia coli</i> Strain BL21 Competent Cell	36
	3.3.4 Transformation of Recombinants Plasmid into <i>E.coli</i>	37
	3.3.5 Primer Reconstitution	37
	3.3.6 Polymerase Chain Reaction (PCR) for Confirmation of Single Colony	38
	3.3.7 Detection of PCR Product by Gel Electrophoresis.....	41
	3.3.8 Gel Image Capture.....	42
3.4	Extraction and Purification of Nucleic Acid	42
	3.4.1 Detection and Quantitation of Nucleic Acid	43
3.5	Sequencing for Confirmation of CYP2C19.....	44
	3.5.1 Cycle Sequencing.....	45
	3.5.2 Purification of Cycle Sequencing Product	46
CHAPTER 4	RESULT	47
4.1	DNA Transformation into BL21 <i>E.coli</i>	47
4.2	Confirmation of Bacterial Colony by PCR Screening.....	48
4.3	Isolation of Plasmid.....	49
	4.3.1 Spectrophotometric Determination of DNA Concentration and Purity	50
4.4	Sequence Analysis.....	50
CHAPTER 5	DISCUSSION	53
CHAPTER 6	CONCLUSION AND RECOMMENDATIONS	62
REFERENCES		63
APPENDICES		70

LIST OF FIGURES

Figure 2.1: Diagrammatic illustration of percentage drug metabolism enzymes.....	5
Figure 2.2: Scheme of P450 reactions.....	12
Figure 2.3: CYP2C clusters in chromosome 10.....	18
Figure 2.4: CYP2C19 alleles.....	19
Figure 2.5: Diagrammatic illustration of basic outline of gene cloning.....	28
Figure 2.6: Overview of study methodology.....	30
Figure 4.1: Culture of recombinat plasmid in <i>E. coli</i> strain BL21.....	47
Figure 4.2: Subculture of recombinat plasmid in <i>E. coli</i> strain BL21.....	47
Figure 4.3: Agarose gel of PCR screening for recombinant plasmids.....	48
Figure 4.4: Gel electrophoresis of extracted plasmids.....	49
Figure 4.5: ClustalW alignment of gene sequence of CYP2C19 and CYP2C19 Reference in NCBI.....	52
Figure 5.1: Sequencing strategy.....	60

LIST OF TABLES

Table 2.1: Some of the inducers and selective inhibitors of human liver P450.....	8
Table 2.2: Classification of human CYP450s based on major substrates class.....	14
Table 2.3: Characterized human P450s.....	15
Table 2.4: Some likely substrates and inhibitors of CYP2C19 enzyme.....	20
Table 2.5: Inter-ethnic distribution of CYP2C19 alleles.....	21
Table 2.6: Drugs which are known to be substrates of the CYP2C19 enzyme.....	22
Table 2.7: CYP2C19 and association with disease.....	25
Table 2.8: Clinical implication of the CYP2C19 polymorphism.....	25
Table 2.9: Enzyme activity of allelic variants of CYP2C19.....	26
Table 3.1: List of chemical and reagents.....	31
Table 3.2: List of instruments.....	33
Table 3.3: Reaction mixtures to cut the TrueORF Entry Vector.....	34
Table 3.4: Ligation reaction mixtures.....	35
Table 3.5: Contents of PCR screening mixture.....	39
Table 3.6: Cycle condition for PCR screening.....	40
Table 3.7: Primers used in sequencing for confirmation of CYP2C19.....	44
Table 3.8: Reaction mixture for the cycle sequencing.....	45
Table 3.9: Cycle condition for sequencing.....	45
Table 3.10: Purification reaction mixture.....	46
Table 4.1: The amount of DNA concentration and purity.....	50

LIST OF ABBREVIATIONS

CaCl ₂	calcium chloride
cDNA	complementary DNA
DNA	deoxyribonucleic acid
dATP	deoxyadenosine triphosphate
dCTP	deoxycytosine triphosphate
dGTP	deoxyguanosine triphosphate
dH ₂ O	distilled water
dNTP	deoxynucleoside triphosphate
dTTP	deoxythymidine triphosphate
EDTA	ethylenediaminetetraacetic acid
EtBr	ethidium bromide
EtOH	ethanol
<i>E. coli</i>	<i>Escherichia coli</i>
gDNA	genomic deoxyribonucleic acid
HCl	hydrochloric acid
H ₂ O	water
KCl	potassium chloride
LB	Luria-Bertani
MgCl ₂	magnesium chloride
NaCl ₂	sodium chloride
NaOAc	sodium acetate
(NH ₄) ₂ SO ₄	ammonium sulfate
NCBI	National Centre for Biotechnology Information
OD	optical density
ORF	open reading frame
PCR	polymerase chain reaction
RE	restriction enzyme
RNA	ribonucleic acid
sec	seconds
Ta	annealing temperature
TAE	tris-acetate EDTA

TBE	tris-borate EDTA
T _m	melting temperature
UK	United Kingdom
USA	United States of America
UV	ultraviolet
v/v	volume to volume
WHO	World Health Organization

LIST OF SYMBOLS

~	approximately
%	percent
'	prime
Ω	Ohm
$^{\circ}\text{C}$	degree celcius
bp	base pairs
g	gram
k	kilo
kb	kilo base
μl	microlitre
U	unit
mg/ml	miligram per mililitre
ml	mililitre
mM	milimolar
ng/ μl	nanogram per microlitre
nm	nanometer
pmol/ μl	picomole per microlitre
rpm	revolution per minute
X	times
x g	times gravity

ABSTRAK

Metabolisme atau biotransformasi obat mengalami perubahan molekul dimana, menukarkan molekul yang tidak polar, molekul obat lipofilik yang aktif secara farmakologi kepada metabolit polar, tidak aktif, atau tidak beracun dalam tubuh sebelum dikumuhkan. Dalam manusia, cytochrome P450 (CYP) enzim adalah pemangkin utama yang terlibat dalam metabolisme obat-obatan dan xenobiotik lain yang memasuki tubuh. Enzim CYP2C19 bertanggungjawab untuk metabolisme obat seperti antidepresan. Penelitian ini dilakukan untuk menghasilkan CYP2C19 enzim rekombinan untuk kajian farmakogenomik. cDNA dihasilkan dari CYP2C19 dan diperoleh dari Origene, USA. Proses pengklonan dilakukan dengan menggunakan RapidShuttling™ Kit (Origene, USA). CYP2C19 dari TrueORF Entry Vector dipindahkan ke vector ekspresi, pEX-C-His. Plasmid yang di ingini diekstrak dengan menggunakan komersial QIAprep Spin Miniprep Kit dan semakan jujukan DNA CYP2C19 disahkan dengan penjujukan DNA menggunakan ABI PRISMA™ 3130xl Genetyx Analyzer. Saiz produk Tindakbalas Polimerase Berantai (TPB) pada gel agarosa adalah pada ~1.5kb. Jujukan DNA enzim CYP2C19 yang di ingini adalah sama seperti di Gene bank. Sebagai kesimpulan, kajian menunjukkan gene *CYP2C19* berjaya diklonkan. Hasil gabungan biologi molekul dan pendedahan relative kepada substrat CYP2C19 dan ujian genetik dapat memberikan kesan positif untuk mengelakkan hasil tindak balas toksikologi yang dihasilkan oleh enzim dan variasi yang ditunjukkan.

ABSTRACT

Drug metabolism or biotransformation of drug undergo molecular alteration in which, it converts nonpolar, lipophilic pharmacologically active drug molecules into polar, inactive, or nontoxic metabolites in the body before excretion. In human, the cytochrome P450 (CYP) enzymes are the major catalysts involved in the metabolism of drugs and other xenobiotics that enter the body. The CYP2C19 enzyme is responsible for the metabolism of several important drugs such as antidepressants. This study was conducted to generate CYP2C19 enzyme recombinant for pharmacogenomics study. Constructed cDNA of CYP2C19 was purchased from Origene, USA. The cloning process was performed by using RapidShuttling™ Kit (Origene, USA). The *CYP2C19* gene from TrueORF Entry Vector was transferred into an expression vector, pEX-C-His. The desired plasmid was extracted using commercial QIAprep Spin Miniprep Kit (Qiagen, Germany) and DNA sequence of CYP2C19 was confirmed by DNA sequencing using ABI PRISMA™ 3130xl Genetyx Analyzer. The size of PCR product was shown at ~1.5kb on agarose gel. Desired DNA sequence of CYP2C19 enzyme shown same sequence as in Gene bank. As a conclusion, *CYP2C19* gene was successfully cloned. The combination of molecular biology and relative exposure to CYP2C19 substrates and genetic testing eventually lead to a better appreciation to avoid toxicological outcomes that may currently result from this enzyme and variations in its expression.